Stroke Study (PROGRESS), the ACE inhibitor plus a diuretic reduced risk of recurrent stroke by 43%. 13 Secondary prevention trials in hypercholesterolemic patients with coronary artery disease have found that lipidlowering treatment with statins reduced the risk of stroke. 14 In the Scandinavian Simvastatin Survival Study (4S), simvastatin reduced risk of stroke by 23% 15; in the Cholesterol and Recurrent Events (CARE) trial, pravastatin reduced stroke risk by 32% 16; and in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial, pravastatin reduced stroke risk by 19%. 17 Similarly, in the West of Scotland Coronary Prevention (WOSCOP) study, a primary prevention trial of men with hypercholesterolemia, statin therapy reduced stroke risk by 19%. 18 In the Heart Protection Study, which involved high-risk patients with atherosclerosis or diabetes and an average LDL cholesterol level of 131 mg/dL, simvastatin reduced stroke risk by 25%. 19